A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia

BACKGROUND: Bictegravir (BIC) co-formulated with emtricitabine (FTC) and tenofovir alafenamide (TAF) is approved by Federal Food and Drug Administration in 2018 for both treatment-naïve and experienced persons living with HIV (PLWH). CASE PRESENTATION: A young man with recently diagnosed human immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Parmar, Kanak, Mekraksakit, Poemlarp, Nugent, Kenneth, Nichols, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872409/
https://www.ncbi.nlm.nih.gov/pubmed/36691090
http://dx.doi.org/10.1186/s12981-023-00501-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872409/
https://www.ncbi.nlm.nih.gov/pubmed/36691090
http://dx.doi.org/10.1186/s12981-023-00501-7

Ejemplares similares